“Dr. Nathan and Dr. Tempany both bring extensive experience navigating unique challenges in prostate research,” said Dr. Amit Vohra, Co-Founder, and CEO of Promaxo. “Their perspectives will be invaluable as we scale and enhance our MRI guided product portfolio.”
OAKLAND, Calif. (PRWEB)
August 24, 2020
Medical imaging, robotics, and AI technology company Promaxo, Inc. (Promaxo), announced Dr. Senthil Nathan and Dr. Clare Tempany as new key members of Promaxo’s advisory board. They bring specialized expertise in urology, radiology and prostate cancer research to navigate the future direction and further development of image-guided diagnosis and treatment capabilities.
“Dr. Nathan and Dr. Tempany both bring extensive experience navigating unique challenges in prostate research,” said Dr. Amit Vohra, Co-Founder, and CEO of Promaxo. “Their perspectives will be invaluable as we scale and enhance our MRI guided product portfolio.”
Dr. Nathan works at the University College Hospital and the Royal Free Hospital in London, as well as serves as a trustee among numerous educational organizations, including the SNJ Educational & Charitable Trust, the SNJ Education Fund, and the Prostate Cancer Research Foundation.
“Having witnessed the value of robotic techniques in urology and been part of the Imperial College team that carried out the world’s first true robotic surgery, I recognize the critical role MRI can play in streamlining prostate cancer treatment,” said Dr. Nathan. “I look forward to working with Promaxo to innovate this industry.”
Additionally, Promaxo welcomes Dr. Clare Tempany, who is the acting Medical Director and Chair of several international clinical trial committees, namely PI-RADS, ECOG-ACRIN in prostate MRI, and MRgFUS for uterine fibroid treatment. Having served as a faculty member at Johns Hopkins Medical Institution as well as the largest women’s hospital in the US, Dr. Tempany will provide invaluable insight toward Promaxo’s medical developments.
“I have been performing interventions under traditional MRI for almost a decade, pioneering the development of prostate cancer diagnosis, and image-guided therapy. I am incredibly impressed with the improvements the Promaxo team has accomplished with their in-office system,” said Dr. Tempany. “Promaxo is at the forefront of medical innovation and I’m excited to be part of it.”
Promaxo’s advisory team now includes 17 experts that cover everything from clinical development and industry forecasting to early market development and market launch. The deep skill sets and industry expertise of this combined team have aided in Promaxo’s rapid growth over the past 18-months.
About Promaxo, Inc.
Promaxo was founded by a team of entrepreneurs and healthcare innovators to develop a minimally-invasive and patient-centric MRI and robotic platform. Based in Oakland, California, and backed by over 60 patents, the company’s mission is to improve lives through state-of-the-art medical imaging, robotics and AI capabilities. With a compact and adaptable MRI, Promaxo is redefining the standard of care by improving the quality and speed of patient screening and interventions. The Company has formed numerous long-term and strategic partnerships with investor groups as it prepares to enter the US market.
To learn more about the technology behind the MRI system and its scope, visit: Promaxo.com.
LinkedIn: Promaxo
Twitter: @Promaxo
Facebook: Promaxo
Media Contact:
Lindsey Hill
Jive PR + Digital
e: lindseyhill@jiveprdigital.com
m: 951.566.6413
http://www.jiveprdigital.com
Share article on social media or email: